Rhythm Launches IMCIVREE in Japan, Bringing the First Approved Treatment for Acquired Hypothalamic Obesity
Key Points
- Rhythm Pharmaceuticals has commercially launched IMCIVREE in Japan for acquired hypothalamic obesity.
- The launch follows regulatory approval in August and inclusion on Japan’s National Health Insurance drug price list.
- IMCIVREE is the first approved treatment in Japan for this condition.
- The supporting Phase 3 trial met its primary endpoint, reporting an 18.8% placebo-adjusted reduction in body mass index.
- Rhythm estimates that approximately 5,000 to 8,000 people in Japan live with acquired hypothalamic obesity.
Rhythm Pharmaceuticals (NASDAQ: RYTM) has launched IMCIVREE (setmelanotide) in Japan, opening a new market for its treatment of acquired hypothalamic obesity.
The commercial launch follows approval by Japan’s Ministry of Health, Labor and Welfare in August 2026 and the drug’s addition to the National Health Insurance price list. According to the announcement, patients in Japan previously had no approved therapy for this disease.
Regulatory Approval and Insurance Listing Support Launch
The announcement marks the transition from regulatory approval to commercial availability in Japan.
Rhythm said it has been building its Japanese team in preparation for the launch. The National Health Insurance listing establishes a key part of the local framework for bringing the treatment to patients.
However, the announcement does not disclose the listed price, detailed patient coverage terms or the number of patients expected to begin treatment.
Phase 3 Trial Reported an 18.8% Placebo-Adjusted BMI Reduction
Japan’s approval was supported by the Phase 3 TRANSCEND trial, which enrolled 142 patients with acquired hypothalamic obesity.
The study included a primary pivotal group of 120 patients, a Japanese cohort of 12 patients and 10 additional supplemental patients.
The global study met its primary endpoint, demonstrating a statistically significant 18.8% placebo-adjusted reduction in body mass index, or BMI. That figure describes the treatment effect relative to placebo; it is not a separately reported result for the Japanese cohort.
The announcement does not provide additional safety findings or a detailed breakdown of outcomes by patient group.
Rhythm Estimates 5,000 to 8,000 Patients in Japan
Rhythm estimates that approximately 5,000 to 8,000 people in Japan live with acquired hypothalamic obesity. Setmelanotide also received orphan drug designation from the Japanese health ministry for this condition.
The population estimate indicates the potential patient pool, not the number of people who will receive IMCIVREE. The announcement provides no forecast for treatment uptake.
Investor Takeaway: A New Commercial Market, With Sales Impact Still Ahead
For RYTM investors, the launch adds Japan to the company’s commercial footprint and brings IMCIVREE to a market where it is the first approved treatment for acquired hypothalamic obesity.
The next measure of progress will be patient uptake and the launch’s contribution to revenue. Rhythm did not provide a Japan sales forecast or quantify the expected financial impact in this announcement.
